Aerami Therapeutics announced today that it entered into a merger agreement with FoxWayne Enterprises Acquisition Corp. (NSDQ:FOXWU). Through the definitive business combination agreement with the special purpose acquisition company (SPAC), Aerami, a developer of inhaled therapies for treating respiratory and chronic diseases, will be listed on the Nasdaq market as “Aerami Therapeutics Holdings, Inc.” Get the […]
dancebiopharm
Dance Biopharm rebrands to Aerami Therapeutics
Dance Biopharm today said it rebranded as Aerami Therapeutics and will move its headquarters to Durham, N.C. The rebranding comes as the company seeks strategic partners for its Dance 501 inhaled human insulin. The company also hopes the rebranding will help progress into pivotal registration studies and expand to include inhaled therapeutics for endocrinology diseases. Get […]
Dance Biopharm, DarioHealth partner up on smart inhaler
Dance Biopharm said today that it has partnered with DarioHealth (NSDQ:DRIO) to integrate Dance’s smart inhaler into DarioHealth’s digital therapeutics program. Durham, N.C.-based Dance Biopharm’s smart inhaler includes vibrating mesh designed to create a soft mist that improves medication coverage in the lung. In clinical trials, the device delivered insulin in mist form with a faster […]
Dance Biopharm raises $21m for insulin delivery device
Dance Biopharm has raised $21 million from 283 investors as part of a $59.2 million offering, according to a document filed with the SEC this week. The privately-held California-based company’s Dance 501 device stores a liquid formulation of recombinant human insulin in a hand-held electronic inhaler. Using a vibrating mesh, the device produces particles of liquid insulin in a […]
Dance Biopharm raises $24m for inhaled insulin device
Privately-held Dance Biopharm said yesterday that it raised $24.5 million in a private equity round to help fund the development of its inhaled insulin product. SternAegis Ventures was the exclusive placement agent for the offering. Molex Ventures, an electronics company working with Dance to develop a connected insulin delivery device, contributed to the round. Get the full […]
Dance Biopharm, Phillips-Medisize ink deal for inhaled insulin device
Privately-held biotech Dance Biopharm and Phillips-Medisize have entered into a joint development deal for a connected drug-delivery device for inhaled insulin. The agreement gives Phillips-Medisize, which already designs and manufactures devices for Dance, the development work for future enhancements of Dance’s devices, as well as commercial manufacturing of the inhaled insulin delivery device when it gets to the market. […]
